ライフサイエンスコーパス: nonvalvular atrial fibrillation

1 on alternative to warfarin for patients with nonvalvular atrial fibrillation.

2 and risk of major bleeding in patients with nonvalvular atrial fibrillation.

3 farin for stroke prevention in patients with nonvalvular atrial fibrillation.

4 ly INR-stable warfarin-treated patients with nonvalvular atrial fibrillation.

5 eventing ischemic stroke among patients with nonvalvular atrial fibrillation.

6 uperior to warfarin for stroke prevention in nonvalvular atrial fibrillation.

7 oral anticoagulants or VKA in patients with nonvalvular atrial fibrillation.

8 pared with warfarin in elderly patients with nonvalvular atrial fibrillation.

9 icant thromboembolic events in patients with nonvalvular atrial fibrillation.

10 g in the 110-mg dose in 18 113 patients with nonvalvular atrial fibrillation.

11 with warfarin for patients at risk who have nonvalvular atrial fibrillation.

12 duced intracranial bleeding in patients with nonvalvular atrial fibrillation.

13 rials comparing VKAs and NOACs (n=71 681) in nonvalvular atrial fibrillation.

14 or stroke prevention in 18 113 patients with nonvalvular atrial fibrillation.

15 7%) had heart failure, and 2,786 (19.3%) had nonvalvular atrial fibrillation.

16 d antithrombotic agents in patients who have nonvalvular atrial fibrillation.

17 strokes in a cohort of 13,559 patients with nonvalvular atrial fibrillation.

18 n patients with mechanical cardiac valves or nonvalvular atrial fibrillation.

19 e initial management strategy for persistent nonvalvular atrial fibrillation.

20 dent than in the management of patients with nonvalvular atrial fibrillation.

21 Of 13,559 adults with nonvalvular atrial fibrillation, 11,526 were studied, 43

22 on) trial demonstrated that in patients with nonvalvular atrial fibrillation (AF) and CHADS2 (congest

23 cy of left atrial appendage (LAA) closure in nonvalvular atrial fibrillation (AF) patients ineligible

24 arin for stroke prophylaxis in patients with nonvalvular atrial fibrillation (AF).

25 al, Minneapolis, Minnesota) in patients with nonvalvular atrial fibrillation and absolute contraindic

26 Patients (n=707) with nonvalvular atrial fibrillation and at least 1 risk fact

27 Cs compared with VKAs to treat patients with nonvalvular atrial fibrillation and concomitant aspirin

28 t the analyses to those newly diagnosed with nonvalvular atrial fibrillation and naive-to-treatment,

29 was a man age 69 years with newly diagnosed nonvalvular atrial fibrillation and no contraindications

30 Of 11082 patients with nonvalvular atrial fibrillation and no known contraindic

31 Among patients with nonvalvular atrial fibrillation, anticoagulation that re

32 Patients with nonvalvular atrial fibrillation are at increased risk of

33 bigatran versus warfarin in the treatment of nonvalvular atrial fibrillation are lacking.

34 In patients with nonvalvular atrial fibrillation at high risk of cardioem

35 to dabigatran and warfarin in patients with nonvalvular atrial fibrillation at risk for stroke witho

36 e-dummy study of rivaroxaban and warfarin in nonvalvular atrial fibrillation, baseline characteristic

37 as the first-choice therapy in patients with nonvalvular atrial fibrillation because these drugs have

38 harged from the hospital with a diagnosis of nonvalvular atrial fibrillation between 1997 and 2008.

39 ated dabigatran or warfarin for treatment of nonvalvular atrial fibrillation between October 2010 and

40 ool in reducing stroke risk in patients with nonvalvular atrial fibrillation but is underused.

41 n preventing stroke and systemic embolism in nonvalvular atrial fibrillation, but has not been evalua

42 ally reduces the risk for ischemic stroke in nonvalvular atrial fibrillation, but its use among ambul

43 be cost-effective for typical patients with nonvalvular atrial fibrillation, but may be cost-effecti

44 with Watchman provides stroke prevention in nonvalvular atrial fibrillation comparable to warfarin,

45 Among patients taking NOACs for nonvalvular atrial fibrillation, concurrent use of amiod

46 ith VKA in anticoagulant-naive patients with nonvalvular atrial fibrillation during the early phase o

47 ischemic strokes and emboli in patients with nonvalvular atrial fibrillation from 4.5% to 1.4% per ye

48 Patients with nonvalvular atrial fibrillation have a 4- to 5-fold incr

49 Strategies in patients with nonvalvular atrial fibrillation have included anticoagul

50 lable to manage stroke risk in patients with nonvalvular atrial fibrillation; however, the cost-effec

51 Patients diagnosed with nonvalvular atrial fibrillation in a 4-hospital institut

52 dabigatran versus warfarin for treatment of nonvalvular atrial fibrillation in general practice sett

53 Nonvalvular atrial fibrillation is a major cause of thro

54 Nonvalvular atrial fibrillation is common in elderly pat

55 rect oral anticoagulants among patients with nonvalvular atrial fibrillation is not known.

56 Nonvalvular atrial fibrillation is the most common arrhy

57 ith dabigatran and warfarin in patients with nonvalvular atrial fibrillation is unknown.

58 Among 91330 patients with nonvalvular atrial fibrillation (mean age, 74.7 years [S

59 Physicians managing patients with nonvalvular atrial fibrillation must consider the risks,

60 Stented subjects with nonvalvular atrial fibrillation (n=2124) were randomized

61 reduces the risk of stroke in patients with nonvalvular atrial fibrillation (NVAF) but increases the

62 unction is associated with increased risk of nonvalvular atrial fibrillation (NVAF) in older adults w

63 f acute kidney injury (AKI) in patients with nonvalvular atrial fibrillation (NVAF) remains unknown.

64 stemic embolism, and cardiovascular death in nonvalvular atrial fibrillation (NVAF) requires continue

65 illation) trial that evaluated patients with nonvalvular atrial fibrillation (NVAF), left atrial appe

66 oembolic risk, particularly in patients with nonvalvular atrial fibrillation (NVAF).

67 efficacy and safety outcomes in Asians with nonvalvular atrial fibrillation (NVAF).

68 trospective cohort study of 1876 adults with nonvalvular atrial fibrillation or flutter seen in prima

69 We included 6022 nonvalvular atrial fibrillation patients from 912 center

70 Among nonvalvular atrial fibrillation patients treated with da

71 compare persistence rates in newly diagnosed nonvalvular atrial fibrillation patients treated with wa

72 hed data of patients >/=18 years of age with nonvalvular atrial fibrillation, randomized to either VK

73 A total of 52 patients with nonvalvular atrial fibrillation underwent LAAC with the

74 tran prescriptions between 2010 and 2012 for nonvalvular atrial fibrillation were sampled (4863 total

75 e an alternative treatment for patients with nonvalvular atrial fibrillation who are less than optima

76 We randomly assigned 2124 participants with nonvalvular atrial fibrillation who had undergone PCI wi

77 tionwide cohort study included patients with nonvalvular atrial fibrillation who initiated dabigatran

78 e database and including 91330 patients with nonvalvular atrial fibrillation who received at least 1

79 l, we randomly assigned 14,264 patients with nonvalvular atrial fibrillation who were at increased ri

80 ied 39,400 patients discharged with incident nonvalvular atrial fibrillation with 0 or 1 CHA2DS2-VASc

81 United States is indicated in patients with nonvalvular atrial fibrillation with acceptable anatomy